Conference call to discuss the data and strategy for the program originally scheduled for 8 a.m. ET on March 18, 2020 has been postponed HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today

Management to host webcast and conference call to review data and program strategy at 8 a.m. ET on March 18, 2020 HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the

HENDERSON, Nev. --(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at the Barclays

BLA for ROLONTIS ® (eflapegrastim) accepted for FDA review - PDUFA date on October 24, 2020 Data from poziotinib Cohort 1 of ZENITH20 accepted for podium presentation on March 18 at 11 th Annual Congress on Pulmonary and Respiratory Medicine in Amsterdam Spectrum plans to hold a conference call

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 20, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the fourth quarter and full year 2019 financial

HENDERSON, Nev. --(BUSINESS WIRE)--Feb. 6, 2020-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the

HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 26, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today reported that its pre-specified primary endpoint in its Phase 2 clinical trial evaluating poziotinib in previously

HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 14, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the

Topline data from Cohort 1 of ZENITH20 trial evaluating poziotinib for NSCLC expected in December Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer Center

HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 31, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today it will host a conference call with management to discuss the third quarter 2019 financial results, provide an

ROLONTIS BLA filing is based on two large pivotal randomized controlled studies that met all primary and secondary endpoints. ROLONTIS is a novel, long-acting granulocyte colony-stimulating factor (G-CSF) seeking an indication for the treatment of neutropenia in patients receiving myelosuppressive

  Publication highlights pre-clinical and clinical activity of poziotinib in lung cancer patients with HER2 mutations and potential future applications using monotherapy and combinations in many different mutated cancers     HENDERSON, Nev. --(BUSINESS WIRE)--Oct.

  HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 25, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at the 2019

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 6, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, is developing poziotinib in non-small cell lung cancer (NSCLC) EGFR exon 20 mutations and beyond.

HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 3, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that an overview of the company's business strategy and development-stage programs will be given at two upcoming

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 8, 2019-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today financial results for the three-month period ended June 30, 2019 .

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 1, 2019-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), announced today it will host a conference call with management to discuss the second quarter 2019 financial results, provide an update on the company's business, and discuss expectations for the future on

Recent pre-clinical data supports development of poziotinib for osimertinib resistance, as well as atypical mutations. Three new cohorts are currently open to patient enrollment in the ZENITH20 trial: Cohort 5 (Expansion Study), Cohort 6 (EGFR osimertinib failures), and Cohort 7 (Atypical EGFR or

HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 20, 2019-- Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the appointment of Elizabeth Czerepak to the Board of Directors. Ms.

Integrated efficacy and safety results in 643 patients were consistent with individual trial results (ADVANCE and RECOVER) The integrated data demonstrated that eflapegrastim provided an absolute risk reduction of severe neutropenia of 6.5% compared to pegfilgrastim in Cycle 1 HENDERSON, Nev.